Cancer is a scourge on society. One in two Americans will be diagnosed with cancer during their lifetime and one in five will die. The five-year cancer survival rates approach 90% when diagnosed in the earliest stages of the disease versus just 10% in the latest stages.
We believe it doesn’t have to be this way.
Assembled a deep clinical evidence library with data collected from more than 1,200 subjects
More than 20 premier cancer institutions around the world participated in our clinical trials
IONIQ's ProLung Test was awarded “Breakthrough Device Designation” by US FDA for its life-enhancing potential
Robust, growing intellectual portfolio of patents and know-how
Salt Lake City, UT, August 10, 2022 – ProLung, Inc. dba IONIQ Sciences, Inc. (“IONIQ” or the “Company”) is honored to be awarded the “Gamechanger Progress Champion 2022” award from ACQ5. The Gamechanger™ Global Awards committee at ACQ5 defines gamechanger as an individual or business that aims
Salt Lake City, UT, July 1, 2022 – ProLung, Inc. dba IONIQ Sciences, Inc. (“IONIQ” or the “Company”) today announced that it has won the ‘2022 Innovation Award’ in the Medical & Health category. The Innovation Award is a prestigious competition and award from Utah Business Magazine
Salt Lake City, UT, June 23, 2022 – ProLung, Inc. dba IONIQ Sciences, Inc. (“IONIQ” or the “Company”) unveiled its next-generation platform called LUNA3™ for early-stage cancer detection. LUNA3 is designed to accelerate the transition of cancer testing from the hospital and doctor’s office into pharmacies and
